实用心脑肺血管病杂志
實用心腦肺血管病雜誌
실용심뇌폐혈관병잡지
PRACTICAL JOURNAL OF CARDIAC CEREBRAL PNEUMAL AND VASCULAR DISEASE
2015年
1期
59-61
,共3页
冠心病%心力衰竭%阿托伐他汀%治疗结果
冠心病%心力衰竭%阿託伐他汀%治療結果
관심병%심력쇠갈%아탁벌타정%치료결과
Coronary disease%Heart failure%Atorvastatin%Treatment outcome
目的：探讨不同剂量阿托伐他汀治疗冠心病慢性心力衰竭的疗效。方法选择2011年1月—2013年1月乐陵市人民医院心内科收治的96例冠心病慢性心力衰竭患者，随机分为对照组和治疗组，每组48例。对照组和治疗组患者在常规治疗基础上分别给予阿托伐他汀20 mg/d、40 mg/d 口服，比较两组患者治疗前后左室射血分数（LVEF）、左室舒张末内径（LVEDD）、左室收缩末内径（LVEXD）及6分钟步行距离（6MWT）及血清N-末端脑利钠肽前体（ NT-proBNP）、超敏C反应蛋白（ hs-CRP）水平；随访6个月，比较两组患者心源性死亡情况和心力衰竭复发住院情况。结果两组患者治疗前LVEF、LVEDD、LVEXD比较，差异无统计学意义（ P﹥0.05）；治疗后治疗组患者LVEF高于对照组，LVEDD、LVEXD低于对照组（ P﹤0.01）。治疗前两组患者血清NT-proBNP、hs-CRP水平及6MWT比较，差异均无统计学意义（ P ﹥0.05）；治疗后治疗组血清 NT -proBNP、hs -CRP 水平低于对照组，6MWT长于对照组（P﹤0.05）。治疗组患者心源性死亡率、心力衰竭复发住院率均低于对照组（P﹤0.05）。结论阿托伐他汀40 mg/d口服治疗冠心病慢性心力衰竭疗效更优，安全性较高，有利于改善患者预后。
目的：探討不同劑量阿託伐他汀治療冠心病慢性心力衰竭的療效。方法選擇2011年1月—2013年1月樂陵市人民醫院心內科收治的96例冠心病慢性心力衰竭患者，隨機分為對照組和治療組，每組48例。對照組和治療組患者在常規治療基礎上分彆給予阿託伐他汀20 mg/d、40 mg/d 口服，比較兩組患者治療前後左室射血分數（LVEF）、左室舒張末內徑（LVEDD）、左室收縮末內徑（LVEXD）及6分鐘步行距離（6MWT）及血清N-末耑腦利鈉肽前體（ NT-proBNP）、超敏C反應蛋白（ hs-CRP）水平；隨訪6箇月，比較兩組患者心源性死亡情況和心力衰竭複髮住院情況。結果兩組患者治療前LVEF、LVEDD、LVEXD比較，差異無統計學意義（ P﹥0.05）；治療後治療組患者LVEF高于對照組，LVEDD、LVEXD低于對照組（ P﹤0.01）。治療前兩組患者血清NT-proBNP、hs-CRP水平及6MWT比較，差異均無統計學意義（ P ﹥0.05）；治療後治療組血清 NT -proBNP、hs -CRP 水平低于對照組，6MWT長于對照組（P﹤0.05）。治療組患者心源性死亡率、心力衰竭複髮住院率均低于對照組（P﹤0.05）。結論阿託伐他汀40 mg/d口服治療冠心病慢性心力衰竭療效更優，安全性較高，有利于改善患者預後。
목적：탐토불동제량아탁벌타정치료관심병만성심력쇠갈적료효。방법선택2011년1월—2013년1월악릉시인민의원심내과수치적96례관심병만성심력쇠갈환자，수궤분위대조조화치료조，매조48례。대조조화치료조환자재상규치료기출상분별급여아탁벌타정20 mg/d、40 mg/d 구복，비교량조환자치료전후좌실사혈분수（LVEF）、좌실서장말내경（LVEDD）、좌실수축말내경（LVEXD）급6분종보행거리（6MWT）급혈청N-말단뇌리납태전체（ NT-proBNP）、초민C반응단백（ hs-CRP）수평；수방6개월，비교량조환자심원성사망정황화심력쇠갈복발주원정황。결과량조환자치료전LVEF、LVEDD、LVEXD비교，차이무통계학의의（ P﹥0.05）；치료후치료조환자LVEF고우대조조，LVEDD、LVEXD저우대조조（ P﹤0.01）。치료전량조환자혈청NT-proBNP、hs-CRP수평급6MWT비교，차이균무통계학의의（ P ﹥0.05）；치료후치료조혈청 NT -proBNP、hs -CRP 수평저우대조조，6MWT장우대조조（P﹤0.05）。치료조환자심원성사망솔、심력쇠갈복발주원솔균저우대조조（P﹤0.05）。결론아탁벌타정40 mg/d구복치료관심병만성심력쇠갈료효경우，안전성교고，유리우개선환자예후。
Objective To explore the clinical effect of different doses of atorvastatin on coronary heart disease patients complicated with chronic heart failure. Methods From January 2011 to January 2013,96 coronary heart disease patients complicated with chronic heart failure were selected in People's Hospital of Leling,and they were randomly divided into control group and treatment group,48 cases in each group. Both groups given routine treatment, and control group given extra atorvastatin(20 mg/d),while treatment group given atorvastatin(40 mg/d). Left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter ( LVEDD ), left ventricular end systolic diameter ( LVEXD ), 6 - minute walking test (6MWT),serum levels of N -terminal brain natriuretic peptide precursor( NT-proBNP) and high -sensitive C -reactive protein( hs-CRP)were compared between the two groups before and after treatment;cardiac mortality and rehospitalization caused by recurrence of heart failure were compared after 6-month fellow-up. Results There was no significant differences of LVEF,LVEDD,LVEXD,serum levels of NT-proBNP and hs-CRP,6MWT between the two groups before treatment( P﹥0. 05);after treatment,LVEF of treatment group was higher than that of control group,LVEDD,LVEXD,serum levels of NT-proBNP and hs-CRP were lower than those of control group,6MWT of treatment group was longer than that of control group (P﹤0. 05). Cardiac mortality and rehospitalization rate of treatment group were lower than those of control group(P﹤0. 05). Conclusion The curative effect of atorvastatin(40 mg/d) in treating coronary heart disease patients complicated with chronic heart failure is better,more safe and more helpful to improve the prognosis.
